Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
2026 World Cup
Rewards

Peptron Plunges 29.94% to 111,600 KRW on CEO Statement Misinterpretation

GateNews
Stocks
Peptron-29.94%
According to Money Today, Peptron stock plummeted 29.94% to 111,600 KRW on July 10, hitting a 52-week low after hitting a peak of 392,500 KRW in November 2025. The selloff was triggered by CEO Choi Ho-il's comments on July 9 at a biotech forum stating that the joint research with U.S. pharma firm Eli Lilly does not include tirzepatide—the core ingredient in Lilly's diabetes and obesity treatments—sparking market concerns that development of the key project had been suspended. The company later clarified that the CEO's statement omitted information due to non-disclosure agreements, and that multiple follow-up substance collaborations with Lilly are proceeding normally according to the October 2024 contract.
View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

15h ago
Peptron Plunges 29.76% on July 10 Amid Eli Lilly Collaboration Dispute
20h ago
Peptron, HLB Stocks Plunge Over 28% on July 10 as Eli Lilly Deal Doubt, FDA Rejection Hit South Korean Biotech
22h ago
KOSPI Plunges 5.35% Overnight to 7,246.79 Amid Panic Selling
07-09 11:25
SK Hynix Stock Drops Over 3 Trading Days, Sparks 'Refund Meme' on July 8
07-09 03:43
Micron Stock Falls Into Bear Market, Down 22.66% Since June Peak to $938.38 on July 7
In-Depth Analysis

PepsiCo Stocks Slip as Analysts Cut Price Targets After Q2 Earnings

Lucas Bennett18h ago

Peptron and HLB Korean Stocks Crash After CEO Statement and FDA Rejection

Lucas Bennett20h ago

Korean Stocks Fall Nearly 20% as Individual Investors Sell 1.27 Trillion Won

Lucas Bennett20h ago
Comment
0/400
No comments